Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 46Leukemia, B-Cell 14Leukemia 14Lymphoma 8Recurrence 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Non-Hodgkin 4Burkitt Lymphoma 4Bronchiolitis Obliterans Syndrome 4Neoplasms 3Lymphoma, Follicular 3Lymphoma, Mantle-Cell 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Hematologic Neoplasms 2Waldenstrom Macroglobulinemia 1Thrombocytopenia 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Paraproteinemias 1Lymphocytosis 1Lymphadenopathy 1Leukemia, Prolymphocytic 1Leukemia, Lymphoid 1Fever 1Fatigue 1Agammaglobulinemia 1

Interventions

fludarabine 3filanesib 2Tacrolimus 2Steroids 2Injections, Subcutaneous 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Dexamethasone 2Bortezomib 2Alemtuzumab 2ofatumumab 1fludarabine phosphate 1Zoledronic Acid 1Whole-Body Irradiation 1Stem Cell Transplantation 1Proteasome Inhibitors 1Mycophenolic Acid 1Lenalidomide 1KW-2478 1Hsp90 inhibitor KU757 1Denosumab 1Cyclophosphamide 1Clonal Hematopoiesis 1Chromatin Immunoprecipitation Sequencing 1CLR1404 1Busulfan 1Blood Cell Count 1ARQ531 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paraproteinemias × ofatumumab × Other hematologic neoplasm × Clear all
NCT01002755 2019-05-07

Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

M.D. Anderson Cancer Center

Phase 2 Completed
36 enrolled 7 charts
Classical hematologyLymphoidOther hematologic neoplasm

Lymphadenopathy, Agammaglobulinemia, Fatigue, Fever, Lymphocytosis, Paraproteinemias, Thrombocytopenia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡